lmbr1l Antibody

What is LMBR1L and why is it important for immunological research?

LMBR1L is a membrane-spanning protein containing nine transmembrane domains that primarily localizes to the endoplasmic reticulum (ER). It functions as a negative regulator of the Wnt/β-catenin pathway, which is essential for proper immune system development . Research has demonstrated that LMBR1L deficiency leads to severely impaired development of all lymphoid lineages, including T cells, B cells, and natural killer (NK) cells, while myeloid cell development remains largely unaffected . LMBR1L accomplishes this regulation by forming a complex with glycoprotein 78 (GP78) and ubiquitin-associated domain containing 2 (UBAC2) to attenuate Wnt signaling in lymphocytes through two mechanisms: preventing the maturation of FZD6 and LRP6 via ubiquitination within the ER, and stabilizing destruction complex proteins .

What are the recommended applications for LMBR1L antibodies in research?

LMBR1L antibodies can be utilized in various experimental techniques including Western blotting, immunoprecipitation, immunohistochemistry, flow cytometry, and immunofluorescence. Based on the literature, LMBR1L antibodies are particularly valuable for studying protein-protein interactions, as LMBR1L has been shown to coimmunoprecipitate with numerous components of the Wnt/β-catenin signaling apparatus (ZNRF3, LRP6, β-catenin, GSK-3α, and GSK-3β) and with proteins involved in ER-associated degradation . When designing experiments, researchers should consider LMBR1L's predominant localization in the ER fraction, as demonstrated through cell fractionation experiments .

What types of samples are suitable for LMBR1L antibody detection?

LMBR1L expression has been detected in various mouse tissues and immune cells, with higher expression observed in the bone marrow, thymus, spleen, and lymphocytes . For researchers studying LMBR1L, suitable sample types include primary lymphocytes (particularly T cells and B cells), lymphoid tissues, bone marrow cells, and cell lines expressing LMBR1L. For developmental studies, researchers should note that LMBR1L plays a role in the differentiation of hematopoietic stem cells (HSCs) into lymphoid-primed multipotent progenitors (LMPPs) and common lymphoid progenitors (CLPs) .

How should researchers validate LMBR1L antibodies for experimental use?

Proper validation of LMBR1L antibodies should include multiple approaches:

• Positive and negative controls: Use tissues or cells known to express or lack LMBR1L. Based on the literature, bone marrow, thymus, and spleen express higher levels of LMBR1L compared to other tissues .

• Knockout validation: Compare antibody reactivity in wild-type versus LMBR1L-deficient samples. The research indicates that CRISPR/Cas9-targeted knockout mutations of LMBR1L have been generated, which could serve as excellent negative controls .

• Molecular weight verification: LMBR1L should appear at the expected molecular weight on Western blots, with recognition of its nine transmembrane-spanning domain structure.

• Subcellular localization: Confirm that the antibody detects LMBR1L primarily in the ER fraction, consistent with published findings from cell fractionation experiments .

What controls are essential when studying LMBR1L in immune cells?

When studying LMBR1L in immune cells, researchers should implement the following controls:

• Cell type-specific controls: Include multiple immune cell populations, as LMBR1L expression varies across cell types. The literature indicates higher expression in lymphocytes compared to myeloid cells .

• Developmental stage controls: Since LMBR1L affects lymphoid development at specific stages, include cells from different developmental stages when relevant.

• Functional redundancy controls: Consider potential compensation by related proteins. While the literature doesn't specifically mention redundancy, this is a standard consideration.

• Pathway activation markers: Include markers of Wnt/β-catenin pathway activation (such as β-catenin levels, TCF-1, and LEF-1) when studying LMBR1L function, as LMBR1L deficiency leads to increased levels of β-catenin and the mature forms of Wnt receptor FZD6 and co-receptor LRP6 .

How can researchers optimize immunoprecipitation experiments with LMBR1L antibodies?

Optimizing immunoprecipitation (IP) experiments with LMBR1L antibodies requires special consideration of its membrane-spanning nature and protein interactions:

• Lysis buffer selection: Use buffers containing mild detergents that effectively solubilize membrane proteins while preserving protein-protein interactions. Since LMBR1L contains nine transmembrane domains and interacts with multiple proteins including GP78, UBAC2, ZNRF3, and components of the Wnt signaling pathway , choose detergents like CHAPS or digitonin.

• Cross-linking consideration: For transient interactions, consider using membrane-permeable crosslinkers prior to cell lysis.

• Co-IP targets: Design co-IP experiments targeting known LMBR1L-interacting proteins such as GP78, UBAC2, ZNRF3, LRP6, β-catenin, GSK-3α, and GSK-3β .

• Subcellular fractionation: Since LMBR1L predominantly localizes to the ER, enriching ER fractions prior to IP may improve detection of LMBR1L-specific interactions .

• Validation with reverse IP: Confirm interactions by performing reverse IPs using antibodies against identified interacting partners and blotting for LMBR1L.

What are the challenges in detecting LMBR1L in different cellular compartments?

Detecting LMBR1L across different cellular compartments presents several challenges:

• Predominant ER localization: LMBR1L is most abundant in the ER fraction as demonstrated by cell fractionation experiments , requiring effective ER isolation techniques.

• Membrane protein extraction: As a nine-transmembrane domain protein, LMBR1L may require specialized membrane protein extraction protocols to maintain structural integrity.

• Fixation methods for microscopy: For immunofluorescence studies, compare different fixation methods (paraformaldehyde, methanol, etc.) to determine which best preserves LMBR1L epitopes while maintaining ER structure.

• Cross-reactivity concerns: Validate antibody specificity across different cellular compartments using appropriate controls, including LMBR1L-deficient cells.

• Signal amplification: For low abundance detection, consider signal amplification methods such as tyramide signal amplification for immunohistochemistry or immunofluorescence applications.

How should researchers interpret conflicting results between different LMBR1L antibodies?

When faced with conflicting results between different LMBR1L antibodies, consider these analytical approaches:

• Epitope mapping: Determine the epitopes recognized by each antibody. Antibodies targeting different domains of LMBR1L may yield different results, especially if certain domains are inaccessible in specific complexes or conditions.

• Post-translational modifications: Investigate whether post-translational modifications affect antibody recognition. While specific modifications of LMBR1L are not explicitly mentioned in the provided literature, as a regulator of ubiquitination , LMBR1L itself may undergo modifications.

• Protein complex formation: LMBR1L interacts with numerous proteins including GP78, UBAC2, and components of the Wnt signaling pathway . These interactions may mask epitopes recognized by certain antibodies.

• Validation using multiple techniques: Confirm results using orthogonal methods. If Western blot and immunohistochemistry results conflict, consider additional techniques like mass spectrometry.

• Knockout controls: Compare results in wild-type versus LMBR1L-deficient samples to determine specificity of each antibody .

What experimental artifacts commonly occur when studying LMBR1L, and how can they be addressed?

Several experimental artifacts may arise when studying LMBR1L:

• Membrane protein aggregation: As a multi-transmembrane protein, LMBR1L may aggregate during sample preparation, resulting in higher molecular weight bands on Western blots. Optimize sample preparation by adjusting detergent types/concentrations and avoiding excessive heating.

• Cross-reactivity with related proteins: Validate antibody specificity against potential cross-reactive proteins, particularly in tissues with low LMBR1L expression.

• Background in ER-rich tissues: Since LMBR1L localizes to the ER , tissues with abundant ER (like secretory cells) may show higher background. Include appropriate negative controls and optimize blocking conditions.

• Fixation artifacts in immunohistochemistry: Test multiple fixation protocols to preserve both LMBR1L epitopes and cellular architecture, particularly for the ER where LMBR1L predominantly localizes .

How can LMBR1L antibodies be used to investigate Wnt/β-catenin signaling in immune cells?

LMBR1L antibodies can provide valuable insights into Wnt/β-catenin signaling regulation in immune cells through these approaches:

• Protein complex analysis: Use LMBR1L antibodies for immunoprecipitation to isolate and characterize the LMBR1L-GP78-UBAC2 complex that regulates Wnt signaling components . This can help identify additional components or regulatory modifications of this complex.

• Co-localization studies: Employ LMBR1L antibodies in co-immunofluorescence experiments to visualize interactions with Wnt pathway components like FZD6, LRP6, and β-catenin in various immune cell types and developmental stages.

• Developmental analysis: Utilize LMBR1L antibodies to track expression during lymphoid development, particularly at the LMPP and CLP stages where LMBR1L deficiency shows pronounced effects .

• Pathway activation monitoring: Compare LMBR1L localization and expression in resting versus activated lymphocytes, correlating with markers of Wnt pathway activation like nuclear β-catenin translocation.

• Degradation complex stability assessment: Combine LMBR1L antibodies with antibodies against destruction complex components (Axin1, DVL2, β-TrCP, GSK-3α/β, CK1) to investigate how LMBR1L stabilizes these proteins, as their reduced expression was observed in LMBR1L-deficient cells .

What methodological approaches should be considered when studying LMBR1L in apoptosis-prone lymphocytes?

When investigating LMBR1L in apoptosis-prone lymphocytes, researchers should consider these methodological approaches:

• Viability-preserving protocols: Since LMBR1L-deficient T cells are predisposed to apoptosis , use gentle isolation techniques and include caspase inhibitors when appropriate to prevent artifactual cell death during sample preparation.

• Time course experiments: Design experiments that capture the temporal relationship between LMBR1L expression/localization and apoptotic events, as LMBR1L-deficient T cells undergo apoptotic cell death in response to proliferative stimuli .

• Multiparameter analysis: Combine LMBR1L antibody staining with markers of apoptosis (Annexin V, cleaved caspase-3) and Wnt pathway activation to correlate LMBR1L levels with cellular outcomes.

• Activation-induced changes: Monitor LMBR1L expression and localization before and after T cell activation, as LMBR1L-deficient T cells showed hallmarks of Wnt/β-catenin activation and underwent apoptotic cell death in response to proliferative stimuli .

• Comparative analysis across lymphocyte subsets: Since LMBR1L deficiency affects multiple lymphoid lineages , compare its expression and function across different lymphocyte populations to identify cell type-specific roles.

What is the relationship between LMBR1L expression and lymphocyte development stages?

The relationship between LMBR1L expression and lymphocyte development stages reveals critical checkpoint functions:

LMBR1L mRNA is detected in various mouse tissues and immune cells, with notably higher expression in the bone marrow, thymus, spleen, and lymphocytes . This expression pattern aligns with its critical role in lymphopoiesis.

How does LMBR1L regulate the Wnt/β-catenin pathway in lymphocytes?

LMBR1L regulates the Wnt/β-catenin pathway in lymphocytes through two distinct molecular mechanisms:

Mechanism 1: ER-associated degradation of Wnt receptors

• LMBR1L forms a complex with GP78 (an E3 ubiquitin ligase) and UBAC2 in the ER

• This complex triggers the ubiquitination and degradation of FZD6 (Wnt receptor) and LRP6 (co-receptor) in the ER

• In LMBR1L-deficient cells, increased levels of mature FZD6 and LRP6 are observed

• Similar effects are seen in GP78-deficient cells, confirming the functional relationship

Mechanism 2: Stabilization of the β-catenin destruction complex

• LMBR1L promotes the stability of multiple destruction complex components, including:

  • Axin1

  • DVL2

  • β-TrCP

  • GSK-3α and GSK-3β

  • Casein kinase 1 (CK1)

• LMBR1L-deficient T cells show reduced protein expression of these components

• This dual regulatory mechanism explains why LMBR1L-deficient cells exhibit increased β-catenin levels and hallmarks of Wnt pathway activation